Network-1 Technologies, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; it does not provide a standalone fourth-quarter income statement. Network-1 develops, licenses and enforces intellectual property, and also holds an investment in clinical-stage biotechnology company ILiAD.
Financial performance and position
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $2.601 million | $0 |
| Operating expenses | $4.836 million | $3.903 million |
| Operating loss | $2.235 million | $3.903 million |
| Net loss | $1.457 million; $0.06 per share | $2.326 million; $0.10 per share |
| Operating cash flow | $331,000 provided | $5.436 million used |
| Cash and marketable securities at year-end | $45.467 million | $48.439 million |
| Working capital at year-end | $44.850 million | $47.359 million |
All FY2023 revenue came from settlements related to the expired Remote Power Patent; four defendants accounted for 90% of revenue. The filing reports no long-term debt and no off-balance-sheet arrangements. Total liabilities were $1.585 million at year-end. Management believes available cash is sufficient for operations for the foreseeable future. Gross margin is not presented as a separate measure.
Changes from FY2022
- Revenue rose from zero to $2.601 million following Remote Power Patent litigation settlements. Operating loss narrowed by $1.668 million, while net loss narrowed by $869,000.
- Interest and dividend income increased to $1.868 million from $1.020 million; marketable securities produced a $525,000 gain versus a $1.351 million loss in 2022.
- FY2022 included one-time ILiAD-related gains of $3.883 million on the equity investment and $271,000 on conversion of a note; neither gain recurred in 2023. Network-1 recorded a $2.003 million share of ILiAD’s losses in 2023, up from $1.639 million.
- Operating cash flow improved by $5.767 million to positive $331,000. Cash dividends paid were $2.371 million, and share repurchases used $966,000.
Outlook, risks and notable items
- No quantified revenue or earnings guidance is provided. Future revenue depends substantially on licensing and litigation outcomes, which management describes as uncertain, lengthy and costly.
- Eight defendants in Remote Power Patent litigation settled in 2023, generating $2.601 million; a further $150,000 payment is conditional and had not been recognized as revenue. Actions against Ubiquiti and Honeywell remain pending.
- Google/YouTube litigation involving the Cox portfolio remains pending, with summary judgment motions outstanding and no trial date set. Network-1’s appeal in the Meta case remained pending at filing.
- In a February 20, 2024 subsequent development, an appellate court upheld dismissal of Network-1’s Netgear complaint, dismissed part of Netgear’s counterclaim, and found a triable issue concerning one licensee.
- The $7 million ILiAD investment is high risk; Network-1 held about 6.7% of ILiAD on a non-fully diluted basis and 5.4% fully diluted at year-end. Its carrying value was $5.249 million.
- The company paid $0.10 per share in 2023 and declared a further $0.05 per share dividend for March 2024. Continuation is subject to Board review. A share repurchase authorization allows up to $5 million over 24 months; a Rule 10b5-1 plan may cover purchases of up to 1 million shares, subject to constraints.
- Key risks include dependence on patent monetization, concentration of revenue, potential patent invalidation or obsolescence, litigation costs and outcomes, competition for IP assets, and uncertainty around ILiAD. Management identified no material cybersecurity impact to date. The auditor issued an unqualified opinion; it reported no critical audit matters.
Investor verification points
- Track rulings, settlement receipts and legal expenses in the Google/YouTube, Meta, Ubiquiti and Honeywell matters, and the remaining Netgear counterclaim issue.
- Confirm whether the conditional $150,000 Remote Power payment is earned and whether any new monetization generates revenue beyond expired-patent settlements.
- Review ILiAD’s funding, clinical progress, financial condition and the recoverability of Network-1’s investment.
- Assess cash deployment, dividend sustainability and repurchases against the company’s lumpy, litigation-dependent revenue profile.
- Reconcile the filing’s inconsistent cumulative share-repurchase totals: one section reports 9,523,982 shares through 2023, while a financial-statement note reports 9,532,982.